Advertisement

Potential role of serum fetuin-A in relation with pro-inflammatory, chemokine and adhesion molecules in diabetic kidney disease: a case–control study

  • Shaik Sarfaraz Nawaz
  • Salini Scaria Joy
  • Yousuf Al Farsi
  • Teena P. George
  • Khalid SiddiquiEmail author
Original Article

Abstract

Inflammatory cytokine, adipokine and adhesion molecules are known to play a key role in pathogenesis of diabetic kidney disease (DKD). In this study, our aim was to investigate the role of fetuin-A in relation with pro-inflammatory cytokines (IL-6, IL-18), adipokines (adiponectin, leptin), chemokine (MCP-1), and adhesion molecules (ICAM-1, VCAM-1) in control and DKD subjects. We recruited a total of 224 type 2 diabetic (T2D) subjects. The control subjects were T2D with a normal albumin excrete (albumin-to-creatinine ratio—ACR ≤ 30 mg/g creatinine) and estimated glomerular filtration rate (eGFR) ≥ 60 (ml/min/1.73 m2), while cases were T2D subjects with albumin excrete (ACR ≥ 30 mg/g creatinine) and eGFR ≤ 60 (ml/min/1.73 m2). FBS, HbA1c, lipid profile (TC, LDL, HDL, triglyceride), ALT, AST, GGT, serum creatinine, BMI, blood pressure was evaluated in all the study subjects. Randox evidence biochip analyzer was used for measuring inflammatory cytokines, adipokines, and adhesion molecules by chemiluminescent assay. Serum fetuin-A and IL-18 were measured by ELISA kits. Serum fetuin-A levels were significantly decreased in DKD cases compare to control group [456.8 (299.2–649.0) µg/ml versus 670.6 (573.0–726.1) µg/ml; p < 0.001)]. Serum fetuin-A levels correlates significantly with IL-6, IL-18, TNF-α, PAI-1, leptin, resistin and ACR (p < 0.001). This study concludes that serum fetuin-A and pro-inflammatory markers (IL-18, IL-6, IL-1α and TNF-α) might play an important role in the pathophysiology and inflammatory process of DKD.

Keywords

DKD T2D ICAM-1 VCAM-1 IL-6 IL-18 Fetuin-A 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

The study has been carried out under compliance of ethical issues. The study was approved by the institutional Review Committee of College of Medicine, King Saud University Riyadh. We used the STROBE case–control checklist for writing our report.

Informed consent

Written informed consent was obtained from each subject.

References

  1. 1.
    International Diabetes Federation (IDF) (2017) http://www.diabetesatlas.org/resources/2017-atlas.html. Accessed 28 Jan 2018
  2. 2.
    Wada J, Makino H (2013) Inflammation and the pathogenesis of diabetic nephropathy. Clin Sci (Lond) 124:139–152.  https://doi.org/10.1042/cs20120198 CrossRefGoogle Scholar
  3. 3.
    Navarro-Gonzalez JF, Mora-Fernandez C, Muros de Fuentes M, Garcia-Perez J (2011) Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol 7:327–340.  https://doi.org/10.1038/nrneph.2011.51 CrossRefGoogle Scholar
  4. 4.
    Choudhary N, Ahlawat RS (2008) Interleukin-6 and C-reactive protein in pathogenesis of diabetic nephropathy: new evidence linking inflammation, glycemic control, and microalbuminuria. Iran J Kidney Dis 2:72–79Google Scholar
  5. 5.
    Nakamura A, Shikata K, Hiramatsu M, Nakatou T, Kitamura T, Wada J, Itoshima T, Makino H (2005) Serum interleukin-18 levels are associated with nephropathy and atherosclerosis in Japanese patients with type 2 diabetes. Diabetes Care 28:2890–2895CrossRefGoogle Scholar
  6. 6.
    Clausen P, Jacobsen P, Rossing K, Jensen JS, Parving HH, Feldt-Rasmussen B (2000) Plasma concentrations of VCAM-1 and ICAM-1 are elevated in patients with Type 1 diabetes mellitus with microalbuminuria and overt nephropathy. Diabetes Med 17:644–649CrossRefGoogle Scholar
  7. 7.
    Guler S, Cakir B, Demirbas B, Yonem A, Odabasi E, Onde U, Aykut O, Gursoy G (2002) Plasma soluble intercellular adhesion molecule 1 levels are increased in type 2 diabetic patients with nephropathy. Horm Res 58:67–70.  https://doi.org/10.1159/000064664 Google Scholar
  8. 8.
    Binkert C, Demetriou M, Sukhu B, Szweras M, Tenenbaum HC, Dennis JW (1999) Regulation of osteogenesis by fetuin. J Biol Chem 274:28514–28520CrossRefGoogle Scholar
  9. 9.
    Ju H, Zhou Z, Sun M, Ji Y, Zhang J, Chen S, Ji J (2014) Association between serum fetuin A and diabetic nephropathy in patients with type 2 diabetes. Chin J Endocrinol Metab 30(7):592–594Google Scholar
  10. 10.
    Al-Rubeaan K, Siddiqui K, Alghonaim M, Youssef AM, AlNaqeb D (2018) The Saudi Diabetic Kidney Disease study (Saudi-DKD): clinical characteristics and biochemical parameters. Ann Saudi Med 38:46–56.  https://doi.org/10.5144/0256-4947.2018.03.01.1010 CrossRefGoogle Scholar
  11. 11.
    American Diabetes Association (2014) Standards of medical care in diabetes—2014. Diabetes Care 37(Suppl 1):S14–S80.  https://doi.org/10.2337/dc14-S014 CrossRefGoogle Scholar
  12. 12.
    Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group (2013) KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 3:1–150CrossRefGoogle Scholar
  13. 13.
    Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF III, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604–612CrossRefGoogle Scholar
  14. 14.
    von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP (2007) Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ 335:806–808.  https://doi.org/10.1136/bmj.39335.541782.AD CrossRefGoogle Scholar
  15. 15.
    Caglar K, Yilmaz MI, Saglam M, Cakir E, Kilic S, Sonmez A, Eyileten T, Yenicesu M, Oguz Y, Tasar M, Vural A, Ikizler TA, Stenvinkel P, Lindholm B (2008) Serum fetuin-a concentration and endothelial dysfunction in chronic kidney disease. Nephron Clin Pract 108:c233–40.  https://doi.org/10.1159/000120209 CrossRefGoogle Scholar
  16. 16.
    Yilmaz MI, Saglam M, Qureshi AR, Carrero JJ, Caglar K, Eyileten T, Sonmez A, Cakir E, Oguz Y, Vural A, Yenicesu M, Stenvinkel P, Lindholm B, Axelsson J (2008) Endothelial dysfunction in type-2 diabetics with early diabetic nephropathy is associated with low circulating adiponectin. Nephrol Dial Transplant 23:1621–1627.  https://doi.org/10.1093/ndt/gfm828 CrossRefGoogle Scholar
  17. 17.
    Lebreton JP, Joisel F, Raoult JP, Lannuzel B, Rogez JP, Humbert G (1979) Serum concentration of human alpha 2 HS glycoprotein during the inflammatory process: evidence that alpha 2 HS glycoprotein is a negative acute-phase reactant. J Clin Invest 64:1118–1129.  https://doi.org/10.1172/jci109551 CrossRefGoogle Scholar
  18. 18.
    Cozzolino M, Galassi A, Biondi ML, Turri O, Papagni S, Mongelli N, Civita L, Gallieni M, Brancaccio D (2006) Serum fetuin-A levels link inflammation and cardiovascular calcification in hemodialysis patients. Am J Nephrol 26:423–429CrossRefGoogle Scholar
  19. 19.
    Gangneux C, Daveau M, Hiron M, Derambure C, Papaconstantinou J, Salier JP (2003) The inflammation-induced down-regulation of plasma Fetuin-A (α2HS-Glycoprotein) in liver results from the loss of interaction between long C/EBP isoforms at two neighbouring binding sites. Nucleic Acids Res 31:5957–5970CrossRefGoogle Scholar
  20. 20.
    Wegner M, Araszkiewicz A, Piorunska-Stolzmann M, Wierusz-Wysocka B, Zozulinska-Ziolkiewicz D (2013) Association between IL-6 concentration and diabetes-related variables in DM1 patients with and without microvascular complications. Inflammation 36:723–728.  https://doi.org/10.1007/s10753-013-9598-y CrossRefGoogle Scholar
  21. 21.
    Suzuki D, Miyazaki M, Naka R, Koji T, Yagame M, Jinde K, Endoh M, Nomoto Y, Sakai H (1995) In situ hybridization of interleukin 6 in diabetic nephropathy. Diabetes 44:1233–1238CrossRefGoogle Scholar
  22. 22.
    Navarro JF, Milena FJ, Mora C, Leon C, Garcia J (2006) Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: effect of angiotensin-converting enzyme inhibition and pentoxifylline administration. Am J Nephrol 26:562–570.  https://doi.org/10.1159/000098004 CrossRefGoogle Scholar
  23. 23.
    Wong CK, Ho AW, Tong PC, Yeung CY, Kong AP, Lun SW, Chan JC, Lam CW (2007) Aberrant activation profile of cytokines and mitogen-activated protein kinases in type 2 diabetic patients with nephropathy. Clin Exp Immunol 149:123–131.  https://doi.org/10.1111/j.1365-2249.2007.03389.x CrossRefGoogle Scholar
  24. 24.
    Fujita T, Ogihara N, Kamura Y, Satomura A, Fuke Y, Shimizu C, Wada Y, Matsumoto K (2012) Interleukin-18 contributes more closely to the progression of diabetic nephropathy than other diabetic complications. Acta Diabetol 49:111–117.  https://doi.org/10.1007/s00592-010-0178-4 CrossRefGoogle Scholar
  25. 25.
    Miyauchi K, Takiyama Y, Honjyo J, Tateno M, Haneda M (2009) Upregulated IL-18 expression in type 2 diabetic subjects with nephropathy: TGF-beta1 enhanced IL-18 expression in human renal proximal tubular epithelial cells. Diabetes Res Clin Pract 83:190–199.  https://doi.org/10.1016/j.diabres.2008.11.018 CrossRefGoogle Scholar
  26. 26.
    Marino E, Cardier JE (2003) Differential effect of IL-18 on endothelial cell apoptosis mediated by TNF-alpha and Fas (CD95). Cytokine 22:142–148CrossRefGoogle Scholar
  27. 27.
    Stuyt RJ, Netea MG, Geijtenbeek TB, Kullberg BJ, Dinarello CA, van der Meer JW (2003) Selective regulation of intercellular adhesion molecule-1 expression by interleukin-18 and interleukin-12 on human monocytes. Immunology 110:329–334CrossRefGoogle Scholar
  28. 28.
    Moriwaki Y, Yamamoto T, Shibutani Y, Aoki E, Tsutsumi Z, Takahashi S, Okamura H, Koga M, Fukuchi M, Hada T (2003) Elevated levels of interleukin-18 and tumor necrosis factor-alpha in serum of patients with type 2 diabetes mellitus: relationship with diabetic nephropathy. Metabolism 52:605–608.  https://doi.org/10.1053/meta.2003.50096 CrossRefGoogle Scholar
  29. 29.
    Mahmoud RA, el-Ezz SA, Hegazy AS (2004) Increased serum levels of interleukin-18 in patients with diabetic nephropathy. Ital J Biochem 53:73–81Google Scholar
  30. 30.
    Amann B, Tinzmann R, Angelkort B (2003) ACE inhibitors improve diabetic nephropathy through suppression of renal MCP-1. Diabetes Care 26:2421–2425CrossRefGoogle Scholar
  31. 31.
    Ye SD, Zheng M, Zhao LL, Qian Y, Yao XM, Ren A, Li SM, Jing CY (2009) Intensive insulin therapy decreases urinary MCP-1 and ICAM-1 excretions in incipient diabetic nephropathy. Eur J Clin Invest 39:980–985.  https://doi.org/10.1111/j.1365-2362.2009.02203.x CrossRefGoogle Scholar
  32. 32.
    Saito T, Saito O, Kawano T, Tamemoto H, Kusano E, Kawakami M, Ishikawa S-e (2007) Elevation of serum adiponectin and CD146 levels in diabetic nephropathy. Diabetes Res Clin Pract 78:85–92CrossRefGoogle Scholar
  33. 33.
    D’Elia JA, Bayliss G, Gleason RE, Weinrauch LA (2016) Cardiovascular-renal complications and the possible role of plasminogen activator inhibitor: a review. Clin Kidney J 9:705–712CrossRefGoogle Scholar
  34. 34.
    Axelsson J, Bergsten A, Qureshi AR, Heimbürger O, Barany P, Lönnqvist F, Lindholm B, Nordfors L, Alvestrand A, Stenvinkel P (2006) Elevated resistin levels in chronic kidney disease are associated with decreased glomerular filtration rate and inflammation, but not with insulin resistance. Kidney Int 69:596–604CrossRefGoogle Scholar

Copyright information

© Springer Nature B.V. 2019

Authors and Affiliations

  1. 1.Strategic Center for Diabetes Research, College of MedicineKing Saud UniversityRiyadhKingdom of Saudi Arabia
  2. 2.University Diabetes Center, College of MedicineKing Saud UniversityRiyadhKingdom of Saudi Arabia

Personalised recommendations